hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06374940 id: Lütfi Kırdar City Hospital briefTitle: Surgical Outcomes of Conventional Hysterectomy or Manipulator-assisted Abdominal Hysterectomy overallStatus: ENROLLING_BY_INVITATION date: 2024-04-17 date: 2024-05-17 date: 2024-05-18 date: 2024-04-19 date: 2024-04-19 name: Dr. Lutfi Kirdar Kartal Training and Research Hospital class: OTHER_GOV briefSummary: Objective: The comparison of surgical outcomes conventional hysterectomy and manipulator-assisted hysterectomy
Secondary outcomes: (1) Postoperative early pain (Visual Analog Score (VAS) at 6th and 24th hours of the surgery) (2) intraoperative complications, (3) postoperative complications conditions: Gynecologic Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE whoMasked: PARTICIPANT count: 140 type: ESTIMATED name: Manipulator-assisted Abdominal Hysterectomy measure: Duration of the surgical procedure measure: Postoperative pain at 6th hours measure: Postoperative pain at 24th hours measure: intraoperative complications measure: Postoperative complications sex: FEMALE minimumAge: 40 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Dr.Lütfi Kırdar City Hospital city: Istanbul zip: 34000 country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06374927 id: PHRASE-2023 briefTitle: Personalised Health Cognitive Assistance for RehAbilitation SystEm (PHRASE): A Feasibility Study acronym: PHRASE-2023 overallStatus: RECRUITING date: 2024-04-25 date: 2024-10-01 date: 2024-10-30 date: 2024-04-19 date: 2024-04-23 name: Donders Centre for Neuroscience class: OTHER briefSummary: The incidence of cognitive and neuromotor impairment caused by strokes has become a growing challenge.
Currently, the support of the patient is organized in a rather fragmented way, and informal care sometimes places a severe burden requiring dedicated support in the patient's social environment. The PHRASE project proposes to deploy rehabilitation technology such as the Rehabilitation Gaming System (RGS) to instil and support a virtuous cycle of stroke patients' recovery in the at-home setting. RGS is an effective advanced digital tool for rehabilitation programs that uses Augmented Reality (AR)- and Virtual Reality (VR)-based gamified training grounded on neuroscientiﬁc principles, that has been shown to promote cognitive and motor recovery after a stroke at the clinic and home.
There are many dedicated cognitive therapies, but most rehabilitation outcomes are mostly limited to the task trained and do not extend to day-to-day function or remain unconvincing. Based on recent literature, the PHRASE RGS-based system can provide an effective tool to address cognitive impairment using VR-based interventions. In a previous study, the neuropsychological test battery was compiled by the neuropsychologist and covered four cognitive domains: 1. basic attention, 2. memory (short-term memory), 3. visuospatial memory, and 4. executive function. All these functions were tested using VR-based tasks. The conclusion of this study confirms the possibility of addressing cognitive impairment effectively using VR-based interventions when properly mapped with clinical scales.
Participants: stroke patients at different time points after stroke (acute, subacute, and chronic), aged over 18 years. The participants will integrate the PHRASE technology into their daily routines in parallel to their regular neurorehabilitation treatment for 6 weeks. conditions: Stroke studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 150 type: ESTIMATED name: Rehabilitation Gaming System (VR-based mobile application) measure: Usability measure: User experience measure: Adherence measure: Acceptance measure: The Montreal Cognitive Assessment (MoCA) measure: Fugl-Meyer Assessment of the sensorimotor function of the upper limb (FMA-UE) measure: Hamilton Depression Rating Scale (HDRS) measure: Fatigue Severity Scale (FSS) measure: Pain Visual Analogue Scale (VAS) measure: Barthel Index (BI) measure: EuroQol - 5 Dimension - 5 Level (EQ-5D-5L) measure: Modified Ashworth scale (MAS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre hospitalier universitaire de Limoges status: NOT_YET_RECRUITING city: Limoges zip: 87000 country: France name: Stephane Mandigout, Dr. role: CONTACT email: stephane.mandigout@unilim.fr lat: 45.83153 lon: 1.25781 facility: Cluj Rehabilitation Hospital status: NOT_YET_RECRUITING city: Cluj-Napoca state: Cluj zip: 400066 country: Romania name: Stefan Strilciuc, PhD. role: CONTACT email: stefan.strilciuc@genomics-center.ro lat: 46.76667 lon: 23.6 facility: Parc Sanitari Sant Joan de Déu status: RECRUITING city: Barcelona country: Spain name: Raffaele Fiorillo, Dr. role: CONTACT email: raffaele.fiorillo@sjd.es name: Raffaele Fiorillo role: PRINCIPAL_INVESTIGATOR lat: 41.38879 lon: 2.15899 facility: IRF La Salle status: NOT_YET_RECRUITING city: Madrid country: Spain name: Miguel Gómez Martínez, Dr. role: CONTACT email: miguel.gomez@lasallecampus.es name: Miguel Gómez Martínez, Dr. role: PRINCIPAL_INVESTIGATOR lat: 40.4165 lon: -3.70256 hasResults: False
nctId: NCT06374914 id: TUO-UR-23-05 briefTitle: Sequential Intravesical Gemcitabine and Docetaxel for Rescue Therapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer Patients overallStatus: NOT_YET_RECRUITING date: 2024-04-09 date: 2026-04-09 date: 2026-04-09 date: 2024-04-19 date: 2024-04-19 name: Dokuz Eylul University class: OTHER briefSummary: Studies in the literature are limited both throughout Turkey and in general. For this reason, as a result of the study that we will create, it will provide us with information for bladder protective treatments in patients who do not respond to BCG therapy in bladder cancer patients. conditions: Bladder Cancer conditions: BCG conditions: Gemcitabine conditions: Docetaxel conditions: Intravesical Instillation studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 120 type: ESTIMATED name: Intravesical Solution measure: Recurrence rate measure: Progression rate measure: Adverse effects of intravesical chemotherapy measure: Intravesical chemotherapy versus radical cystectomy measure: treatment change sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Dokuz Eylul University Faculty of Medicine Department of Urology city: Izmir state: Other (Non U.s.) zip: 35330 country: Turkey name: Muhammed Selcuk Ozer, Medical Doctor role: CONTACT phone: +905543078941 email: mseljukozer@gmail.com name: Ozan Bozkurt, Professor role: CONTACT email: drozanbozkurt@gmail.com name: Ozan Bozkurt, Professor role: PRINCIPAL_INVESTIGATOR lat: 38.41273 lon: 27.13838 hasResults: False
nctId: NCT06374901 id: IRB-2024-311 briefTitle: Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment. overallStatus: NOT_YET_RECRUITING date: 2024-04-25 date: 2026-03-31 date: 2028-03-31 date: 2024-04-19 date: 2024-04-19 name: Xiangdong Cheng class: OTHER name: Liaoning Tumor Hospital & Institute name: Shanxi Province Cancer Hospital name: Sichuan Cancer Hospital and Research Institute name: The Second Affiliated Hospital of Harbin Medical University briefSummary: To evaluate the efficacy of Tislelizumab in combination with chemotherapy versus chemotherapy in neoadjuvant treatment of patients with MHC-II positive (IHC≥2+) and locally advanced gastric/gastroesophageal junction adenocarcinoma by evaluating the main pathologic response rate (MPR). conditions: Gastric Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 134 type: ESTIMATED name: Tislelizumab name: SOX/XELOX measure: MRP (Main pathological response) measure: pCR (pathologic complete response) measure: DFS (Disease free survival) measure: OS (Overall survival) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) city: Hangzhou state: Zhejiang country: China lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06374888 id: CVL009-2002 briefTitle: Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2026-09-30 date: 2027-07-30 date: 2024-04-19 date: 2024-04-19 name: Convalife (Shanghai) Co., Ltd. class: INDUSTRY briefSummary: To evaluate the efficacy of nilatinib maleate tablets combined with capecitabine in the treatment of HER2-positive advanced esophageal/esophagogastric junction/gastric adenocarcinoma with brain metastasis. conditions: Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Her2-positive advanced esophageal/esophagogastric junction/gastric adenocarcinoma with brain metastases primaryPurpose: TREATMENT masking: NONE count: 28 type: ESTIMATED name: Neratinib maleate in combination with capecitabine measure: Objective response rates of the central nervous system as assessed by the Independent Imaging Evaluation Committee based on RECIST1.1 measure: Central nervous response rate measure: Objective response rates outside the central nervous system measure: Disease control rate measure: Duration of reaction measure: Clinical benefit rate measure: overall survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06374875 id: 24-213 briefTitle: Fibrosis Lessens After Metabolic Surgery acronym: FLAMES overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2029-05-31 date: 2029-12-31 date: 2024-04-19 date: 2024-04-19 name: Ali Aminian class: OTHER briefSummary: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma. Patients with MASH are also at risk for cardiovascular disease and mortality. There is no universally approved medication for MASH. Weight loss remains the cornerstone of MASH treatment.
Patients meeting the inclusion and exclusion criteria and who give informed consent will be enrolled in the trial and undergo the baseline liver biopsy (if none available). Approximately 120 patients with MASH and liver fibrosis (F1-F4 in baseline liver biopsy) will be randomized in a 1:1 ratio to metabolic surgery or medical treatment (incretin-based therapies ± other medical therapies for MASH) and followed for 2 years at which time a repeat liver biopsy will be performed for the assessment of the primary end point. conditions: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) conditions: Non-Alcoholic Fatty Liver Disease conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH) conditions: Liver Fibrosis conditions: Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Patients will be randomized in a 1:1 ratio into 1 of the 2 arms using a computer-generated randomization plan, stratified to ensure that there are equal number of patients with/without T2DM and with/without F4 (cirrhosis) according to the baseline liver biopsy in each treatment group (surgical group vs non-surgical group). The participant sites are regrouped into three geographic regions. All patients in each region will be randomized separately to have equal number of patients with/without T2DM and with/without F4 in each treatment group in each region. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Patients and investigators will not be blinded to treatment assignment. The treatment assignment will remain unknown until the patient is randomized after meeting all eligibility requirements.
nctId: NCT06374862 id: PI2024_843_0008 briefTitle: Effects of Specific Thoracic Spine Mobilizations on Muscle Activity in a Healthy Volunteer Population acronym: RACHI-MOB overallStatus: RECRUITING date: 2024-03-28 date: 2025-10 date: 2025-10 date: 2024-04-19 date: 2024-04-19 name: Centre Hospitalier Universitaire, Amiens class: OTHER briefSummary: In this study, the investigators will examine the effect of manual therapy on the thoracic spine and its impact on the muscular strength gain of the thoracic extensors. Treatment with manual therapy, as described by Maitland, consists of a specific mobilization of the thoracic spine in the postero-anterior direction on the transverse and spiny processes of the thoracic vertebrae. To ensure the relevance of the measures, and to better control the occurrence of biases inherent to the practice of manual therapy, the investigators constituted three distinct groups: an intervention group, a control group and a group without intervention. In short, this methodology will allow us to explore in detail the effects of specific spinal mobilization on motor control, while taking into account placebo response elements and natural variations in the results conditions: Musculoskeletal Manipulations conditions: Range of Motion conditions: Muscle Strength conditions: Peripheral Joints in Upper Quarters studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 156 type: ESTIMATED name: mobilization name: no effect measure: electrical activity assessment of the spine extensor muscles using EMG sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU Amiens Picardie status: RECRUITING city: Amiens state: Picardie zip: 80054 country: France name: Vicente BELTRAN AIBAR role: CONTACT phone: 03.22.45.59.92 email: BeltranAibar.Vicente@chu-amiens.fr name: François-Régis Sarhan role: SUB_INVESTIGATOR lat: 49.9 lon: 2.3 hasResults: False
nctId: NCT06374849 id: PI2023_843_0173 briefTitle: Intraoperative Sufentanil and Chronic Postsurgical Pain in Non-major Scheduled Abdominal Surgery acronym: ISPAIN overallStatus: RECRUITING date: 2024-03-17 date: 2026-04 date: 2026-07 date: 2024-04-19 date: 2024-04-19 name: Centre Hospitalier Universitaire, Amiens class: OTHER briefSummary: Several risk factors for chronic postoperative pain have been identified. A series of studies have shown that administrating intraoperatively a high dose of Remifentanil is associated with an increased incidence of CPSP. These findings highlight a risk factor for CPSP that the anaesthetist can influence on, but they however remain limited to remifentanil. To this day, no study have attempted to evaluate the existence of such an association between the incidence of CPSP and the intraoperative administration of sufentanil doses. Improved knowledge of the long-term nociceptive impact of intraoperative sufentanil administration would enable better therapeutic adaptation according to each patient's risk.
In the field of CPSP, non-major abdominal surgeries remain poorly studied. This is due to their lower risk of CPSP than other surgeries such as orthopaedic, mammary or thoracic surgery. Nevertheless, they constitute a large number of daily surgical procedures. The estimated incidence of CPSP in non-major abdominal surgery appears in several studies to be between 15 and 20% The aim of this study is to evaluate the correlation between the intraoperative administration of sufentanil doses and the incidence of CPSP at 3 months in patients undergoing non-major scheduled abdominal surgery. conditions: Chronic Postsurgical Pain conditions: Chronic Pain conditions: Abdominal Surgery conditions: Sufentanil conditions: Risk Factors studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 855 type: ESTIMATED name: phone interview measure: Incidence of CPSP measure: Post-operative pain intensity measure: Post-operative pain intensity sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU Amiens-Picardie status: RECRUITING city: Amiens zip: 80054 country: France name: Paul TARPIN, MD role: CONTACT phone: 0322087980 email: Tarpin.Paul@chu-amiens.fr name: Ottilie Fumery, MD role: SUB_INVESTIGATOR name: Stephane BAR, Pr role: SUB_INVESTIGATOR name: Benjamin Mestan, MD role: SUB_INVESTIGATOR lat: 49.9 lon: 2.3 hasResults: False
nctId: NCT06374836 id: nWMO 2024.040 briefTitle: The Contractile Response of the Thoracic Aorta to Vasoactive Substances acronym: AorticContract overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-08 date: 2024-12 date: 2024-04-19 date: 2024-04-24 name: Catharina Ziekenhuis Eindhoven class: OTHER name: Maastricht University briefSummary: Hypertension affects 32-35% of the global adult population. Despite many drugs being available hypertension is not controlled in 50% of the over 500 million treated people leaving patients with an elevated blood pressure for life.
In the development of isolated systolic hypertension, the aorta plays a pivotal role. With each heartbeat, the heart empties its stroke volume into the large arteries. These arteries, particularly the thoracic part of the aorta, temporarily distend to buffer the stroke volume and thereby dampen the pressure fluctuation: they have a Windkessel function. When this function is reduced (and arterial stiffness is increased), the heart needs to contract more forcefully during ejection, leading to isolated systolic hypertension.
Likely, the aorta is not just a passive structure (the aorta as an elastic 'bicycle tube'). Rather, the smooth muscle cells in the aorta wall can presumably actively change the aorta's dimension through vasoconstriction/-dilation. If this is the case, such vasoconstriction/-dilation will have direct consequences for the aorta's Windkessel function and, since this Windkessel function directly influences the blood pressure flucturation, also for hypertension and its progression. Therefore, the aim of this study is to quantify the thoracic aorta's ability to vasoconstrict, and to assess whether this contractility is related to specific predictors.
During the study we will measure in the operating room the thoracic descending and ascending aortic diameter with transoesopahgeal echocardiography (part of standard clinical care), before and after administration of vasoactive drugs (phenylephrine and norepinephrine; also part of standard clinical care). During these measurements we will simultanesouly measure peripheral arterial blood pressure and an electrocardiogram (ECG, to monitor sympathetic activity as estimated using heart rate variability analysis). Measurements will be performed at Catharina Hospital Eindhoven, the Netherlands (NL), where patients undergo elective cardiac surgery. Using the data obtained, we will 1) establish and quantify the in vivo contractility of the human thoracic aorta, and 2) study whether and to which extent potential predictors (age, sex, smoking status, antihypertensive medication use/class, mean arterial pressure, pulse pressure as an indirect measure of arterial stiffness, diabetes, chronic kidney disease, total cholesterol, and sympathetic activity) influence contractility conditions: Human Thoracic Aorta Contractility studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 98 type: ESTIMATED name: Phenylephrine measure: To establish and quantify the in vivo contractility of the human thoracic aorta measure: To quantify the magnitude of contractile response measure: To study whether and to which extent potential predictors influence contractility. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Catharina hospital city: Eindhoven state: Noord-Brabant zip: 5623 EJ country: Netherlands name: Frederique de Raat, Msc. role: CONTACT phone: +31615137244 email: frederique.d.raat@catharinaziekenhuis.nl name: Angélique Burmanje, Msc. role: CONTACT phone: +316 44 15 00 18 email: angelique.burmanje@catharinaziekenhuis.nl lat: 51.44083 lon: 5.47778 hasResults: False
nctId: NCT06374823 id: IIT2023-020-002 briefTitle: Multiple Electrolytes Injection (II) and Normal Saline on Hyperchloremia in Severe Hemorrhagic Stroke acronym: MERIT overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-12 date: 2026-12 date: 2024-04-19 date: 2024-04-19 name: Capital Medical University class: OTHER briefSummary: Normal saline (0.9% sodium chloride), a classical crystalloid solution, is widely used to maintain fluid balance, volume resuscitation and dilute drugs during clinical practice. However, the chloride concentration of normal saline (154mmol/L) is much higher than human plasma, and a large amount of infusion may lead to iatrogenic hyperchloremia in ICU patients. In contrast, the concentrations of Multiple electrolytes II is more similar to those of plasma and is considered to be a better fluid choice than normal saline. conditions: Critical Care conditions: Hyperchloremia conditions: Hemorrhagic Stroke studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 342 type: ESTIMATED name: Multiple Electrolyte name: Normal Saline measure: Hyperchloremia measure: Hyperchloremia acidosis measure: Plasma osmolality measure: AKI measure: RRT measure: hospital length of stay measure: ICU length of stay measure: hospitalization expense sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Shijitan Hospital city: Beijing state: Beijing zip: 100038 country: China name: Jian-Xin Zhou, MD role: CONTACT phone: +8613801183875 email: zhoujx.cn@icloud.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06374810 id: CCB1 briefTitle: Does Conscious Connected Breathwork Reduce Symptoms of Anxiety? overallStatus: COMPLETED date: 2023-09-21 date: 2023-12-20 date: 2023-12-20 date: 2024-04-19 date: 2024-04-22 name: Richard Blake class: OTHER briefSummary: The goal of this clinical trial is to test whether conscious connected breathwork reduces symptoms of anxiety in people with mild to severe anxiety symptoms, as measured by the Zung Self Rating Anxiety Scale.
Participants will participate in 1, 90 minute breath workshop per week for 6 weeks. These sessions will be held on Zoom by 2 facilitators. Participants will also be given a 10 minute recording of a guided conscious connected breathwork session that they will be encouraged to complete daily. conditions: Anxiety studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Participants were randomly assigned to either the breathwork group or they were told that they had been placed on a waitlist and that they would participate in the 2nd cohort, which would take place after the 1st 6-week program had been completed.
Participants in the breathwork groups were also given a 10 minute guided conscious connected breathwork recording. They were advised to do this daily to support the integration of their process. This was not mandatory. At the end of the study participants were asked how often they used the guided self-practice. The frequency of use of the self-practice was used a covariate. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Participants in group 2 were told that the trial was full but actually they were just placed in the placebo control group. whoMasked: PARTICIPANT count: 108 type: ACTUAL name: Conscious Connected Breathwork name: Placebo waitlist measure: Changes in anxiety symptoms sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CIIS city: San Francisco state: California zip: 94103 country: United States lat: 37.77493 lon: -122.41942 hasResults: False